Table 2.
Summary of demographic and baseline characteristics
| Variable | Sunitinib (n = 147) | IFN-α (n = 153) |
| Age (year), mean ± SD | 61.0 ± 10.9 | 60.0 ± 9.5 |
| Male, n (%) | 94 (63.9) | 124 (81.0) |
| Race, n (%) | ||
| White | 145 (98.6) | 148 (96.7) |
| Black | 1 (0.7) | 2 (1.3) |
| Asian | 1 (0.7) | 1 (0.7) |
| Others | 0 (0.0) | 2 (1.3) |
| Country, n (%) | ||
| France | 40 (27.2) | 42 (27.5) |
| Germany | 8 (5.4) | 7 (4.6) |
| Italy | 8 (5.4) | 16 (10.5) |
| Poland | 54 (36.7) | 48 (31.4) |
| Russian Federation | 12 (8.2) | 17 (11.1) |
| Spain | 15 (10.2) | 12 (7.8) |
| United Kingdom | 10 (6.8) | 11 (7.2) |
| Weight (kg), mean ± SD | 76.8 ± 15.6 | 79.0 ± 15.6 |
| ECOG performance status, n (%) | ||
| 0 | 84 (57.1) | 84 (54.9) |
| 1 | 63 (42.9) | 66 (43.1) |
| 2a | 0 (0.0) | 3 (2.0) |
| Previous nephrectomy (%) | 89 | 89 |
| Previous radiation therapy (%) | 15 | 13 |
| No. of sites of metastases 1/2/≥3 (%) | 18/26/57 | 24/29/49 |
a
All subjects had ECOG performance status of zero or one at the time eligibility was determined; three subjects in the IFN-α group had ECOG performance status of two on the day of starting the study treatment.
IFN-α, interferon-alpha; ECOG, Eastern Cooperative Oncology Group; SD, standard deviation.